DNA methylation as a universal biomarker

References

• Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol.19(3), 165–171 (2009).
   PubMed Web of Science ®Google Scholar
• Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev. Mol. Diagn.9(3), 243–257 (2009).
   PubMed Web of Science ®Google Scholar
• Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol. Cancer7, 81 (2008).
   PubMed Web of Science ®Google Scholar
• Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol.8(11), 1056–1072 (2009).
   PubMed Web of Science ®Google Scholar
• Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med.46(9), 1241–1249 (2009).
   PubMed Web of Science ®Google Scholar
• Sananbenesi F, Fischer A. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol. Chem.390(11), 1145–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Dehan P, Kustermans G, Guenin S et al. DNA methylation and cancer diagnosis: new methods and applications. Expert Rev. Mol. Diagn.9(7), 651–657 (2009).
   PubMed Web of Science ®Google Scholar
• Evertts AG, Zee BM, Garcia BA. Modern approaches for investigating epigenetic signaling pathways. J. Appl. Physiol. DOI: 00007.2010v1 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Hurd PJ, Nelson CJ. Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief Funct. Genomic Proteomic8(3), 174–183 (2009).
   PubMedGoogle Scholar
• Weng YI, Huang TH, Yan PS. Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. Methods Mol. Biol.590, 165–176 (2009).
   PubMedGoogle Scholar
• Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology150(9), 4003–4011 (2009).
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA89(5), 1827–1831 (1992).
   PubMed Web of Science ®Google Scholar
• Reeben M, Prydz H. An improved method for detection of 5-methylcytosine by PCR-based genomic sequencing. Biotechniques16(3), 416–417 (1994).
   PubMed Web of Science ®Google Scholar
• Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res.29(13), E65–E65 (2001).
   PubMedGoogle Scholar
• Munson K, Clark J, Lamparska-Kupsik K, Smith SS. Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res.35(9), 2893–2903 (2007).
   PubMed Web of Science ®Google Scholar
• Rein T, DePamphilis ML, Zorbas H. Identifying 5-methylcytosine and related modifications in DNA genomes. Nucleic Acids Res.26(10), 2255–2264 (1998).
   PubMed Web of Science ®Google Scholar
• Harrison J, Stirzaker C, Clark SJ. Cytosines adjacent to methylated CpG sites can be partially resistant to conversion in genomic bisulfite sequencing leading to methylation artifacts. Anal. Biochem.264(1), 129–132 (1998).
   PubMed Web of Science ®Google Scholar
• Warnecke PM, Stirzaker C, Melki JR et al. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res.25(21), 4422–4426 (1997).
   PubMed Web of Science ®Google Scholar
• Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res.28(8), E32 (2000).
   PubMed Web of Science ®Google Scholar
• Umbricht CB, Evron E, Gabrielson E et al. Hypermethylation of 14–13–3 sigma (stratifin) is an early event in breast cancer. Oncogene20(26), 3348–3353 (2001).
   PubMed Web of Science ®Google Scholar
• Fackler MJ, McVeigh M, Mehrotra J et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res.64(13), 4442–4452 (2004).
   PubMed Web of Science ®Google Scholar
• Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. Am. Fam. Physician80(8), 815–820 (2009).
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Pitman MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch. Pathol. Lab. Med.133(3), 454–464 (2009).
   PubMed Web of Science ®Google Scholar
• Steinberg W. The clinical utility of the CA 19–19 tumor-associated antigen. Am. J. Gastroenterol.85(4), 350–355 (1990).
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol.112(1), 40–46 (2009).
   PubMed Web of Science ®Google Scholar
• Leman ES, Getzenberg RH. Biomarkers for prostate cancer. J. Cell. Biochem.108(1), 3–9 (2009).
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Wojciechowski J, Tainsky MA. Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput. Methods Mol. Biol.520, 21–38 (2009).
   PubMedGoogle Scholar
• Waldman SA, Terzic A. A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer. FEBS J.276(8), 2157–2164 (2009).
   PubMed Web of Science ®Google Scholar
• Hung EC, Chiu RW, Lo YM. Detection of circulating fetal nucleic acids: a review of methods and applications. J. Clin. Pathol.62(4), 308–313 (2009).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Feng Q, Toure P et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol.24(26), 4262–4269 (2006).
   PubMed Web of Science ®Google Scholar
• Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids – a promising, non-invasive tool for early detection of several human diseases. FEBS Lett.581(5), 795–799 (2007).
   PubMed Web of Science ®Google Scholar
• Ellinger J, Albers P, Perabo FG et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol.182(1), 324–329 (2009).
   PubMed Web of Science ®Google Scholar
• Kamat AA, Bischoff FZ, Dang D et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol. Ther.5(10), 1369–1374 (2006).
   PubMed Web of Science ®Google Scholar
• Wu TL, Zhang D, Chia JH et al. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta321(1–2), 77–87 (2002).
   PubMed Web of Science ®Google Scholar
• Fatouros IG, Destouni A, Margonis K et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin. Chem.52(9), 1820–1824 (2006).
   PubMed Web of Science ®Google Scholar
• Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr. Opin. Mol. Ther.6(3), 273–278 (2004).
   PubMedGoogle Scholar
• Wong TS, Man MW, Lam AK et al. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur. J. Cancer39(13), 1881–1887 (2003).
   PubMed Web of Science ®Google Scholar
• Ramirez JL, Taron M, Balana C et al. Serum DNA as a tool for cancer patient management. Rocz. Akad. Med. Bialymst.48, 34–41 (2003).
   PubMedGoogle Scholar
• Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J. Mol. Diagn.11(1), 60–65 (2009).
   PubMed Web of Science ®Google Scholar
• Illingworth RS, Bird AP. CpG islands – ‘a rough guide’. FEBS Lett.583(11), 1713–1720 (2009).
   PubMed Web of Science ®Google Scholar
• Skvortsova TE, Rykova EY, Tamkovich SN et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer94(10), 1492–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Benlloch S, Galbis-Caravajal JM, Martin C et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer107(8), 1859–1865 (2006).
   PubMed Web of Science ®Google Scholar
• Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate68(1), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann. NY Acad. Sci.945, 51–58 (2001).
   PubMed Web of Science ®Google Scholar
• Papadopoulou E, Davilas E, Sotiriou V et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. NY Acad. Sci.1075, 235–243 (2006).
   PubMed Web of Science ®Google Scholar
• Tani N, Ichikawa D, Ikoma D et al. Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. Anticancer Res.27(2), 1207–1212 (2007).
   PubMed Web of Science ®Google Scholar
• Ellinger J, El Kassem N, Heukamp LC et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol.179(1), 346–352 (2008).
   PubMed Web of Science ®Google Scholar
• Koyanagi K, Mori T, O’Day SJ et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res.66(12), 6111–6117 (2006).
   PubMed Web of Science ®Google Scholar
• Wei SH, Balch C, Paik HH et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res.12(9), 2788–2794 (2006).
   PubMed Web of Science ®Google Scholar
• Liggett TE, Melnikov AA, Yi Q-L et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer116(7), 1674–1680. (2010).
   PubMed Web of Science ®Google Scholar
• Lindenmeyer MT, Kern C, Sparna T et al. Microarray analysis reveals influence of the sesquiterpene lactone parthenolide on gene transcription profiles in human epithelial cells. Life Sci.80(17), 1608–1618 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Issa JP, Kurzrock R et al. Decitabine effect on tumor global DNA methylation and other parameters in a Phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res.15(11), 3881–3888 (2009).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10(6), 1871–1874 (2004).
   PubMed Web of Science ®Google Scholar
• Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res.10(15), 4933–4938 (2004).
   PubMed Web of Science ®Google Scholar
• Dunn J, Baborie A, Alam F et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer101(1), 124–131 (2009).
   PubMed Web of Science ®Google Scholar
• Wei SH, Brown R, Huang TH. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann. NY Acad. Sci.983, 243–250 (2003).
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Invest.27(8), 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• Martens JW, Nimmrich I, Koenig T et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res.65(10), 4101–4117 (2005).
   PubMed Web of Science ®Google Scholar
• Hartmann O, Spyratos F, Harbeck N et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res.15(1), 315–323 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yoshida K, Wada Y et al. Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol. Rep.18(2), 329–336 (2007).
   PubMed Web of Science ®Google Scholar
• Brabender J, Arbab D, Huan X et al. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer. Ann. Surg. Oncol.16(5), 1378–1383 (2009).
   PubMed Web of Science ®Google Scholar
• Augustine CK, Yoo JS, Potti A et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin. Cancer Res.15(2), 502–510 (2009).
   PubMed Web of Science ®Google Scholar
• Wei SH, Chen CM, Strathdee G et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res.8(7), 2246–2252 (2002).
   PubMed Web of Science ®Google Scholar
• Fiegl H, Millinger S, Mueller-Holzner E et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res.65(4), 1141–1145 (2005).
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int. J. Urol.16(1), 17–22 (2009).
   PubMed Web of Science ®Google Scholar
• de Maat MF, van de Velde CJ, van der Werff MP et al. Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J. Clin. Oncol.26(14), 2327–2335 (2008).
   PubMed Web of Science ®Google Scholar
• Jarmalaite S, Andrekute R, Scesnaite A et al. Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J. Cancer Res. Clin. Oncol. DOI: 10.1007/s00432-009-0725-y (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Owen CM, Segars JH Jr. Imprinting disorders and assisted reproductive technology. Semin. Reprod. Med.27(5), 417–428 (2009).
   PubMed Web of Science ®Google Scholar
• Hattori M, Torii C, Yagihashi T et al. Diagnosis of Russell–Silver syndrome by the combined bisulfite restriction analysis-denaturing high-performance liquid chromatography assay. Genet. Test Mol. Biomarkers13(5), 623–630 (2009).
   PubMed Web of Science ®Google Scholar
• Bird A. The methyl-CpG-binding protein MeCP2 and neurological disease. Biochem. Soc. Trans.36(Pt 4), 575–583 (2008).
   PubMed Web of Science ®Google Scholar
• Behrens MI, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer’s disease? Curr. Alzheimer Res.6(3), 196–204 (2009).
   PubMed Web of Science ®Google Scholar
• Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr. Mol. Med.9(3), 315–323 (2009).
   PubMed Web of Science ®Google Scholar
• Feng J, Fan G. The role of DNA methylation in the central nervous system and neuropsychiatric disorders. Int. Rev. Neurobiol.89, 67–84 (2009).
   PubMed Web of Science ®Google Scholar
• Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer’s disease. PLoS ONE4(8), e6617 (2009).
   PubMed Web of Science ®Google Scholar
• Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS ONE3(7), e2698 (2008).
   PubMed Web of Science ®Google Scholar
• Costa E, Chen Y, Dong E et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev. Neurother.9(1), 87–98 (2009).
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Rosse RB, Mastropaolo J, Long KD, Gaskins BL. Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time? Clin. Neuropharmacol.31(2), 104–119 (2008).
   PubMed Web of Science ®Google Scholar
• Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res.85(9), 2006–2016 (2007).
   PubMed Web of Science ®Google Scholar
• Kobow K, Jeske I, Hildebrandt M et al. Increased reelin promoter methylation is associated with granule cell dispersion in human temporal lobe epilepsy. J. Neuropathol. Exp. Neurol.68(4), 356–364 (2009).
   PubMed Web of Science ®Google Scholar
• Dion V, Wilson JH. Instability and chromatin structure of expanded trinucleotide repeats. Trends Genet.25(7), 288–297 (2009).
   PubMed Web of Science ®Google Scholar
• Kiran M, Chawla YK, Kaur J. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India. Cancer Genet. Cytogenet.195(2), 112–119 (2009).
   PubMedGoogle Scholar
• Nakajima T, Yamashita S, Maekita T et al. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int. J. Cancer124(4), 905–910 (2009).
   PubMed Web of Science ®Google Scholar
• Flatley JE, McNeir K, Balasubramani L et al. Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. Cancer Epidemiol. Biomarkers Prev.18(10), 2782–2789 (2009).
   PubMed Web of Science ®Google Scholar